RAHWAY, N.J. - Merck & Co. (NYSE:MRK) announced a reorganization of its Human Health business into two units and appointed two executives to lead them, according to a press release statement. The ...

Merck forecasts 2026 sales below Wall Street estimates Co plans to offer clarity on $70 billion growth opportunities by 2027 Merck anticipates $2.5 billion impact from generic competition, Medicare ...

Disclosed in the latest SEC filing, a significant insider purchase on January 28, involves Johannes Oosthuizen, President at Merck & Co (NYSE:MRK). What Happened: A Form 4 filing with the U.S.

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin cancer after five years, new data confirming its prolonged benefit show.

We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Merck & Co., Inc. is among the most undervalued stocks. On December 12, 2025, Morgan Stanley analyst Terence Flynn ...

Merck & Co. has agreed to acquire Cidara Therapeutics for approximately $9.2 billion, the companies said, in a deal designed to bolster the buyer’s antiviral pipeline with a Phase III drug designed to ...

Merck MRK2.18%increase; green up pointing triangle & Co. has struck a $9.2 billion deal to buy biotechnology company Cidara Therapeutics in a move that bolsters the drugmaker’s respiratory portfolio ...

Merck & Co. logo displayed on the exterior of their research facility in San Francisco, Calif., on Sep. 21, 2020. This story was originally published on BioPharma Dive. To receive daily news and ...

Oct 30 (Reuters) - Merck & Co (MRK.N), opens new tab posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset falling sales from human papillomavirus ...

Merck & Co. has doubled down on its partnership with Variational AI, striking a deal worth up to $349 million to collaborate on small molecule candidates against two targets. Variational disclosed a ...

The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.

Thank you very much for joining us today for the lunch session. My name is Mohit Bansal. I'm Biotech and Pharma Analyst here at Wells Fargo. And I'm very happy to have the Merck management team with ...